MX367668B - Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos. - Google Patents
Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.Info
- Publication number
- MX367668B MX367668B MX2015013232A MX2015013232A MX367668B MX 367668 B MX367668 B MX 367668B MX 2015013232 A MX2015013232 A MX 2015013232A MX 2015013232 A MX2015013232 A MX 2015013232A MX 367668 B MX367668 B MX 367668B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antibodies
- flavivirus
- neutralizing antibodies
- present
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title abstract 3
- 230000003472 neutralizing effect Effects 0.000 title 1
- 101710204837 Envelope small membrane protein Proteins 0.000 abstract 1
- 206010057199 Flaviviral infections Diseases 0.000 abstract 1
- 235000002222 Irvingia smithii Nutrition 0.000 abstract 1
- 244000308605 Irvingia smithii Species 0.000 abstract 1
- 101710145006 Lysis protein Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 241000710886 West Nile virus Species 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792336P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/028310 WO2014144061A2 (en) | 2013-03-15 | 2014-03-14 | Flavivirus neutralizing antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015013232A MX2015013232A (es) | 2015-12-11 |
| MX367668B true MX367668B (es) | 2019-08-30 |
Family
ID=51538297
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013232A MX367668B (es) | 2013-03-15 | 2014-03-14 | Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos. |
| MX2019010339A MX2019010339A (es) | 2013-03-15 | 2015-09-15 | Anticuerpos neutralizadores de flavivirus y metodos de uso de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010339A MX2019010339A (es) | 2013-03-15 | 2015-09-15 | Anticuerpos neutralizadores de flavivirus y metodos de uso de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9822166B2 (de) |
| EP (3) | EP4292657A3 (de) |
| JP (2) | JP6427552B2 (de) |
| AU (2) | AU2014227909C1 (de) |
| BR (1) | BR112015021341B1 (de) |
| CA (1) | CA2901358C (de) |
| MX (2) | MX367668B (de) |
| PH (1) | PH12015502164B1 (de) |
| SG (1) | SG11201507359SA (de) |
| WO (1) | WO2014144061A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9822166B2 (en) * | 2013-03-15 | 2017-11-21 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| WO2018010789A1 (en) * | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| WO2018071913A2 (en) | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| CA3091144A1 (en) * | 2018-03-01 | 2019-09-06 | Igm Biosciences, Inc. | Igm fc and j-chain mutations that affect igm serum half-life |
| EP3773707A1 (de) * | 2018-04-11 | 2021-02-17 | Tychan Pte. Ltd. | Verfahren und zusammensetzungen zur behandlung von gelbfieber |
| JP7471555B2 (ja) | 2020-02-20 | 2024-04-22 | 国立感染症研究所長 | フラビウイルス交差中和抗体及び医薬組成物 |
| RU2757488C1 (ru) * | 2020-11-10 | 2021-10-18 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Универсальный рекомбинантный вектор pBuc и плазмидная генетическая конструкция pBuc-7B4, обеспечивающая синтез и секрецию антитела 7В4 против вируса Западного Нила в клетках животных и полученная с использованием указанного вектора pBuc |
| CN116514963B (zh) * | 2023-04-21 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 广谱识别黄病毒属病毒e蛋白的抗体fy2及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0814159B1 (de) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| CA2118921A1 (en) | 1991-09-17 | 1993-04-01 | Jose Goulon | Electron detector device for spectroscopic analyses of surfaces under x-ray excitation |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| EP0823941A4 (de) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Menschliche antikörper aus xenomäusen |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| UA89481C2 (uk) * | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| WO2005123774A2 (en) | 2004-06-15 | 2005-12-29 | Erol Fikrig | Antibodies to west nile virus polypeptides |
| WO2010043977A2 (en) * | 2008-10-13 | 2010-04-22 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
| SG193554A1 (en) | 2011-03-29 | 2013-11-29 | Roche Glycart Ag | Antibody fc variants |
| US9822166B2 (en) * | 2013-03-15 | 2017-11-21 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2014
- 2014-03-14 US US14/777,324 patent/US9822166B2/en active Active
- 2014-03-14 AU AU2014227909A patent/AU2014227909C1/en active Active
- 2014-03-14 MX MX2015013232A patent/MX367668B/es active IP Right Grant
- 2014-03-14 CA CA2901358A patent/CA2901358C/en active Active
- 2014-03-14 EP EP23181586.1A patent/EP4292657A3/de active Pending
- 2014-03-14 EP EP19213985.5A patent/EP3689902B1/de active Active
- 2014-03-14 BR BR112015021341-3A patent/BR112015021341B1/pt active IP Right Grant
- 2014-03-14 SG SG11201507359SA patent/SG11201507359SA/en unknown
- 2014-03-14 JP JP2016502756A patent/JP6427552B2/ja active Active
- 2014-03-14 WO PCT/US2014/028310 patent/WO2014144061A2/en active Application Filing
- 2014-03-14 EP EP14764455.3A patent/EP2971042B1/de active Active
-
2015
- 2015-09-15 PH PH12015502164A patent/PH12015502164B1/en unknown
- 2015-09-15 MX MX2019010339A patent/MX2019010339A/es unknown
-
2017
- 2017-11-20 US US15/818,491 patent/US10400032B2/en active Active
-
2018
- 2018-06-06 AU AU2018204011A patent/AU2018204011C1/en active Active
- 2018-10-29 JP JP2018202677A patent/JP6734902B2/ja active Active
-
2019
- 2019-07-17 US US16/514,439 patent/US10899825B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502164A1 (en) | Flavivirus neutralizing antibodies and methods of use thereof | |
| PH12018502348A1 (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| TW201613970A (en) | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy | |
| MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
| MD4655C1 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
| PH12018500199A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| EA201892793A1 (ru) | Анти-hla-g специфические антитела | |
| EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
| PH12016501937A1 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| EA201391713A1 (ru) | Нейтрализующие вирус иммунодефицита человека антитела и способы их применения | |
| MX352338B (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| EA201391170A1 (ru) | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PH12020550025A1 (en) | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof | |
| EA201891925A1 (ru) | Антитела к cd40 с усиленной агонистической активностью | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
| PH12016501444A1 (en) | Antibodies against f glycoprotein of hendra and nipah viruses | |
| UY36820A (es) | Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh | |
| MY179251A (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| MX2019002696A (es) | Metodos para tratar o prevenir una infeccion del virus del zika. | |
| MX2016011885A (es) | Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |